

A Eden Evins

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8172995/publications.pdf>

Version: 2024-02-01

132
papers

8,297
citations

57681

46
h-index

54771

88
g-index

134
all docs

134
docs citations

134
times ranked

9356
citing authors

#	ARTICLE	IF	CITATIONS
1	Polygenic score for cigarette smoking is associated with ever electronic cigarette use in a college-aged sample. <i>Addiction</i> , 2022, 117, 1071-1078.	1.7	4
2	Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults. <i>JAMA Network Open</i> , 2022, 5, e222106.	2.8	34
3	Randomised, pragmatic, waitlist controlled trial of cannabis added to prescription opioid support on opioid dose reduction and pain in adults with chronic non-cancer pain: study protocol. <i>BMJ Open</i> , 2022, 12, e064457.	0.8	2
4	Performance Metrics of Substance Use Disorder Care Among Medicaid Enrollees in New York, New York. <i>JAMA Health Forum</i> , 2022, 3, e221771.	1.0	3
5	Developing a Sound Body: Open Trial Results of a Group Healthy Lifestyle Intervention for Young Adults with Psychosis. <i>Community Mental Health Journal</i> , 2021, 57, 864-871.	1.1	2
6	Efficacy and Safety of Pharmacotherapeutic Smoking Cessation Aids in Schizophrenia Spectrum Disorders: Subgroup Analysis of EAGLES. <i>Psychiatric Services</i> , 2021, 72, 7-15.	1.1	25
7	Online recovery support meetings can help mitigate the public health consequences of COVID-19 for individuals with substance use disorder. <i>Addictive Behaviors</i> , 2021, 113, 106661.	1.7	27
8	Alcohol substitution during one month of cannabis abstinence among non-treatment seeking youth. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 107, 110205.	2.5	6
9	Patient Experience and Predictors of Improvement in a Group Behavioral and Educational Intervention for Individuals With Diabetes and Serious Mental Illness: Mixed Methods Case Study. <i>Journal of Participatory Medicine</i> , 2021, 13, e21934.	0.7	2
10	Validation of brief screening measures for depression and anxiety in young people with substance use disorders. <i>Journal of Affective Disorders</i> , 2021, 282, 1021-1029.	2.0	20
11	Variation in Cannabinoid Metabolites Present in the Urine of Adults Using Medical Cannabis Products in Massachusetts. <i>JAMA Network Open</i> , 2021, 4, e215490.	2.8	4
12	Estimation of risk of neuropsychiatric adverse events from varenicline, bupropion and nicotine patch versus placebo: secondary analysis of results from the EAGLES trial using Bayes factors. <i>Addiction</i> , 2021, 116, 2816-2824.	1.7	7
13	Assessing Changes in Symptoms of Depression and Anxiety During Four Weeks of Cannabis Abstinence Among Adolescents. <i>Frontiers in Psychiatry</i> , 2021, 12, 689957.	1.3	6
14	Sex Differences in Neuropsychological Functioning are Domain-Specific in Adolescent and Young Adult Regular Cannabis Users. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 592-606.	1.2	6
15	Integrated Smoking Cessation for Smokers With Serious Mental Illness: Protocol for a Convergent Mixed Methods Implementation Evaluation Study. <i>JMIR Research Protocols</i> , 2021, 10, e25390.	0.5	1
16	Virtual Group Therapy Programs – “The Wave of the Future”. <i>Journal of Adolescent Health</i> , 2021, 69, 527.	1.2	3
17	Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence. <i>Journal of Psychopharmacology</i> , 2020, 34, 197-210.	2.0	10
18	White matter integrity differences associated with post-traumatic stress disorder are not normalized by concurrent marijuana use. <i>Psychiatry Research - Neuroimaging</i> , 2020, 295, 111017.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of pharmacotherapies for smoking cessation in anxiety disorders: Subgroup analysis of the randomized, active- and placebo-controlled EAGLES trial. <i>Depression and Anxiety</i> , 2020, 37, 247-260.	2.0	14
20	Effects of various antipsychotics on driving-related cognitive performance in adults with schizophrenia. <i>Journal of Psychiatric Research</i> , 2020, 131, 152-159.	1.5	2
21	Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, e5-e31.	2.5	133
22	Effect of a Comprehensive Cardiovascular Risk Reduction Intervention in Persons With Serious Mental Illness. <i>JAMA Network Open</i> , 2020, 3, e207247.	2.8	58
23	A placebo-controlled randomized trial of D-cycloserine augmentation of cue exposure therapy for smoking cessation. <i>Cognitive Behaviour Therapy</i> , 2019, 48, 65-76.	1.9	9
24	Characteristics of Adult Cigarette Smokers Who "Relight" and the Effects of Exposure to Tobacco Smoke Constituents. <i>Nicotine and Tobacco Research</i> , 2019, 21, 1206-1212.	1.4	9
25	Resting-state Brain Connectivity Predicts Weight Loss and Cognitive Control of Eating Behavior After Vertical Sleeve Gastrectomy. <i>Obesity</i> , 2019, 27, 1846-1855.	1.5	22
26	Cross-domain correlates of cannabis use disorder severity among young adults. <i>Addictive Behaviors</i> , 2019, 93, 212-218.	1.7	7
27	Safety and efficacy of first-line smoking cessation pharmacotherapies in bipolar disorders: Subgroup analysis of a randomized clinical trial. <i>Journal of Affective Disorders</i> , 2019, 256, 267-277.	2.0	16
28	Smoking cessation in people with serious mental illness. <i>Lancet Psychiatry</i> , 2019, 6, 563-564.	3.7	3
29	Delta-9-tetrahydrocannabinol intoxication is associated with increased prefrontal activation as assessed with functional near-infrared spectroscopy: A report of a potential biomarker of intoxication. <i>NeuroImage</i> , 2019, 197, 575-585.	2.1	10
30	Effect of Cigarette Rod Length on Smokers Switching to SPECTRUM Cigarettes. <i>American Journal of Health Behavior</i> , 2019, 43, 380-392.	0.6	1
31	Predictors of Neuropsychiatric Adverse Events with Smoking Cessation Medications in the Randomized Controlled EAGLES Trial. <i>Journal of General Internal Medicine</i> , 2019, 34, 862-870.	1.3	15
32	Reducing the Nicotine Content of Cigarettes: Effects in Smokers With Mental Health Conditions and Socioeconomic Disadvantages. <i>Nicotine and Tobacco Research</i> , 2019, 21, S26-S28.	1.4	7
33	Neuropsychiatric Safety and Efficacy of Varenicline, Bupropion, and Nicotine Patch in Smokers With Psychotic, Anxiety, and Mood Disorders in the EAGLES Trial. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 108-116.	0.7	67
34	Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. <i>Addiction</i> , 2018, 113, 1507-1516.	1.7	58
35	Anterior insula activation during inhibition to smoking cues is associated with ability to maintain tobacco abstinence. <i>Addictive Behaviors Reports</i> , 2018, 7, 40-46.	1.0	21
36	A Call to Action for Treatment of Comorbid Tobacco and Alcohol Dependence. <i>JAMA Psychiatry</i> , 2018, 75, 121.	6.0	3

#	ARTICLE	IF	CITATIONS
37	Nicotine Increases Activation to Anticipatory Valence Cues in Anterior Insula and Striatum. <i>Nicotine and Tobacco Research</i> , 2018, 20, 851-858.	1.4	20
38	Nicotine-induced activation of caudate and anterior cingulate cortex in response to errors in schizophrenia. <i>Psychopharmacology</i> , 2018, 235, 789-802.	1.5	10
39	Phase IIb Trial of an ± 7 Nicotinic Receptor Partial Agonist With and Without Nicotine Patch for Withdrawal-Associated Cognitive Deficits and Tobacco Abstinence. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 307-316.	0.7	7
40	T266. Memory Deficits are Reversible With Sustained Cannabis Abstinence Among Cannabis Using Adolescents. <i>Biological Psychiatry</i> , 2018, 83, S233.	0.7	2
41	Need for Cardiovascular Risk Reduction in Persons With Serious Mental Illness: Design of a Comprehensive Intervention. <i>Frontiers in Psychiatry</i> , 2018, 9, 786.	1.3	16
42	Acceptability of SPECTRUM Research Cigarettes among Participants in Trials of Reduced Nicotine Content Cigarettes. <i>Tobacco Regulatory Science (discontinued)</i> , 2018, 4, 573-585.	0.2	9
43	Maintenance pharmacotherapy normalizes the relapse curve in recently abstinent tobacco smokers with schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2017, 183, 124-129.	1.1	15
44	A two-site, two-arm, 34-week, double-blind, parallel-group, randomized controlled trial of reduced nicotine cigarettes in smokers with mood and/or anxiety disorders: trial design and protocol. <i>BMC Public Health</i> , 2017, 17, 100.	1.2	13
45	Prolonged cannabis withdrawal in young adults with lifetime psychiatric illness. <i>Preventive Medicine</i> , 2017, 104, 40-45.	1.6	13
46	Improved Depressive Symptoms in Adults with Schizophrenia During a Smoking Cessation Attempt with Varenicline and Behavioral Therapy. <i>Journal of Dual Diagnosis</i> , 2017, 13, 168-178.	0.7	15
47	Achieving Smoking Cessation in Individuals with Schizophrenia: Special Considerations. <i>CNS Drugs</i> , 2017, 31, 471-481.	2.7	76
48	Predictors of tobacco abstinence in outpatient smokers with schizophrenia or bipolar disorder treated with varenicline and cognitive behavioral smoking cessation therapy. <i>Addictive Behaviors</i> , 2017, 71, 89-95.	1.7	11
49	Using Functional Near-Infrared Spectroscopy to Measure Effects of Delta 9-Tetrahydrocannabinol on Prefrontal Activity and Working Memory in Cannabis Users. <i>Frontiers in Human Neuroscience</i> , 2017, 11, 488.	1.0	11
50	Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network meta-analysis. <i>Addiction</i> , 2016, 111, 599-612.	1.7	92
51	Neural mechanisms of sensitivity to peer information in young adult cannabis users. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2016, 16, 646-661.	1.0	20
52	Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. <i>Lancet, The</i> , 2016, 387, 2507-2520.	6.3	929
53	A contingency management method for 30-days abstinence in non-treatment seeking young adult cannabis users. <i>Drug and Alcohol Dependence</i> , 2016, 167, 199-206.	1.6	23
54	Early onset marijuana use is associated with learning inefficiencies.. <i>Neuropsychology</i> , 2016, 30, 405-415.	1.0	41

#	ARTICLE	IF	CITATIONS
55	Lower gray matter density and functional connectivity in the anterior insula in smokers compared with never smokers. <i>Addiction Biology</i> , 2016, 21, 972-981.	1.4	42
56	Altered Neural Processing to Social Exclusion in Young Adult Marijuana Users. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2016, 1, 152-159.	1.1	11
57	Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review. <i>JAMA Psychiatry</i> , 2016, 73, 292.	6.0	621
58	Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions. <i>Biological Psychiatry</i> , 2016, 80, 274-283.	0.7	55
59	Does Cannabis Cause, Exacerbate or Ameliorate Psychiatric Disorders? An Oversimplified Debate Discussed. <i>Neuropsychopharmacology</i> , 2016, 41, 393-401.	2.8	53
60	Detecting treatment-covariate interactions using permutation methods. <i>Statistics in Medicine</i> , 2015, 34, 2035-2047.	0.8	7
61	Effective Cessation Strategies for Smokers with Schizophrenia. <i>International Review of Neurobiology</i> , 2015, 124, 133-147.	0.9	20
62	Effect of Social Influence on Effort-Allocation for Monetary Rewards. <i>PLoS ONE</i> , 2015, 10, e0126656.	1.1	9
63	Single dose propranolol does not affect physiologic or emotional reactivity to smoking cues. <i>Psychopharmacology</i> , 2015, 232, 1619-1628.	1.5	38
64	Young adult cannabis users report greater propensity for risk-taking only in non-monetary domains. <i>Drug and Alcohol Dependence</i> , 2015, 147, 26-31.	1.6	31
65	T. Kishi and N. Iwata: Varenicline for smoking cessation in people with schizophrenia: systematic review meta-analysis. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 269-270.	1.8	2
66	Treatment of Tobacco Use Disorders in Smokers with Serious Mental Illness. <i>Harvard Review of Psychiatry</i> , 2015, 23, 90-98.	0.9	74
67	Reward Responsiveness Varies by Smoking Status in Women with a History of Major Depressive Disorder. <i>Neuropsychopharmacology</i> , 2015, 40, 1940-1946.	2.8	24
68	Maintenance Treatment With Varenicline for Smoking Cessation in Patients With Schizophrenia and Bipolar Disorder. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 145.	3.8	180
69	Systematic review and meta-analysis of opioid antagonists for smoking cessation. <i>BMJ Open</i> , 2014, 4, e004393.	0.8	26
70	Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. <i>Pituitary</i> , 2014, 17, 150-156.	1.6	53
71	Acute effects of mecamylamine and varenicline on cognitive performance in non-smokers with and without schizophrenia. <i>Psychopharmacology</i> , 2014, 231, 765-775.	1.5	23
72	Finding the Right Match: Mindfulness Training May Potentiate the Therapeutic Effect of Nonjudgment of Inner Experience on Smoking Cessation. <i>Substance Use and Misuse</i> , 2014, 49, 586-594.	0.7	18

#	ARTICLE	IF	CITATIONS
73	Impulsive Social Influence Increases Impulsive Choices on a Temporal Discounting Task in Young Adults. <i>PLoS ONE</i> , 2014, 9, e101570.	1.1	31
74	Reassessing the Safety of Varenicline. <i>American Journal of Psychiatry</i> , 2013, 170, 1385-1387.	4.0	16
75	Does Using Marijuana Increase the Risk for Developing Schizophrenia?. <i>Journal of Clinical Psychiatry</i> , 2013, 74, e08.	1.1	8
76	The Effect of Marijuana Use on the Risk for Schizophrenia [CME]. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1463-1468.	1.1	26
77	Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. <i>Drug and Alcohol Dependence</i> , 2012, 120, 7-13.	1.6	45
78	Possible role of nicotine for the treatment of mild cognitive impairment. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 531-533.	1.4	1
79	Varenicline as a smoking cessation aid in schizophrenia: effects on smoking behavior and reward sensitivity. <i>Psychopharmacology</i> , 2012, 219, 25-34.	1.5	38
80	Anterior cingulate proton spectroscopy glutamate levels differ as a function of smoking cessation outcome. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1709-1713.	2.5	23
81	A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking in Females. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 597-602.	0.7	11
82	Neural Substrates of Attentional Bias for Smoking-Related Cues: An fMRI Study. <i>Neuropsychopharmacology</i> , 2010, 35, 2339-2345.	2.8	122
83	Brain Reactivity to Smoking Cues Prior to Smoking Cessation Predicts Ability to Maintain Tobacco Abstinence. <i>Biological Psychiatry</i> , 2010, 67, 722-729.	0.7	371
84	Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR). <i>Psychiatry Research</i> , 2010, 176, 99-102.	1.7	42
85	Review: bupropion increases abstinence from smoking without affecting mental state in people with schizophrenia. <i>Evidence-Based Mental Health</i> , 2010, 13, 120-120.	2.2	3
86	Oral glycine administration increases brain glycine/creatine ratios in men: A proton magnetic resonance spectroscopy study. <i>Psychiatry Research - Neuroimaging</i> , 2009, 173, 143-149.	0.9	24
87	Single dose of a dopamine agonist impairs reinforcement learning in humans: Evidence from event-related potentials and computational modeling of striatal-cortical function. <i>Human Brain Mapping</i> , 2009, 30, 1963-1976.	1.9	117
88	A placebo-controlled study of sildenafil effects on cognition in schizophrenia. <i>Psychopharmacology</i> , 2009, 202, 411-417.	1.5	65
89	A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with Schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2009, 119, 457-465.	2.2	38
90	Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 165-169.	0.7	79

#	ARTICLE	IF	CITATIONS
91	Waist Circumference is the Best Anthropometric Predictor for Insulin Resistance in Nondiabetic Patients with Schizophrenia Treated with Clozapine but not Olanzapine. <i>Journal of Psychiatric Practice</i> , 2009, 15, 251-261.	0.3	19
92	Brain fMRI reactivity to smoking-related images before and during extended smoking abstinence.. <i>Experimental and Clinical Psychopharmacology</i> , 2009, 17, 365-373.	1.3	57
93	Single dose of a dopamine agonist impairs reinforcement learning in humans: Behavioral evidence from a laboratory-based measure of reward responsiveness. <i>Psychopharmacology</i> , 2008, 196, 221-232.	1.5	217
94	Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia. <i>Psychopharmacology</i> , 2008, 199, 89-98.	1.5	107
95	Once-weekly d-cycloserine effects on negative symptoms and cognition in schizophrenia: An exploratory study. <i>Schizophrenia Research</i> , 2008, 106, 320-327.	1.1	126
96	A Single Dose of Nicotine Enhances Reward Responsiveness in Nonsmokers: Implications for Development of Dependence. <i>Biological Psychiatry</i> , 2008, 63, 1061-1065.	0.7	111
97	Cortical Thickness Abnormalities in Cocaine Addictionâ€”A Reflection of Both Drug Use and a Pre-existing Disposition to Drug Abuse?. <i>Neuron</i> , 2008, 60, 174-188.	3.8	150
98	Posttraumatic stress disorder, cognitive function and quality of life in patients with schizophrenia. <i>Psychiatry Research</i> , 2008, 159, 140-146.	1.7	49
99	High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. <i>Schizophrenia Research</i> , 2008, 102, 88-95.	1.1	69
100	The Effects of Transdermal Nicotine on Cognition in Nonsmokers with Schizophrenia and Nonpsychiatric Controls. <i>Neuropsychopharmacology</i> , 2008, 33, 480-490.	2.8	217
101	A Controlled Trial of Bupropion Added to Nicotine Patch and Behavioral Therapy for Smoking Cessation in Adults With Unipolar Depressive Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 660-666.	0.7	59
102	A Randomized, Double-Blind, Placebo-Controlled Trial of Long-Acting Risperidone in Cocaine-Dependent Men. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 480-486.	1.1	35
103	Predictors of Early Abstinence in Smokers With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1743-1750.	1.1	43
104	Smoking Cessation in Patients With Psychiatric Disorders. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2008, 10, 52-58.	0.6	16
105	A 12-Week Double-Blind, Placebo-Controlled Study of Bupropion SR Added to High-Dose Dual Nicotine Replacement Therapy for Smoking Cessation or Reduction in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 380-386.	0.7	159
106	Reply to Comments by Dr Babbar. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 240.	0.7	0
107	Sexual functioning, psychopathology and quality of life in patients with schizophrenia. <i>Schizophrenia Research</i> , 2007, 94, 119-127.	1.1	60
108	Smoking Cessation in Patients With Psychiatric Disorders. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1404-1410.	1.1	9

#	ARTICLE	IF	CITATIONS
109	A double-blind, placebo-controlled trial of adjunctive donepezil in treatment-resistant mania. <i>Bipolar Disorders</i> , 2006, 8, 75-80.	1.1	41
110	Inositol augmentation of lithium or valproate for bipolar depression. <i>Bipolar Disorders</i> , 2006, 8, 168-174.	1.1	69
111	Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2006, 113, 121-125.	2.2	17
112	Dietary Intake Profile of Patients with Schizophrenia. <i>Annals of Clinical Psychiatry</i> , 2006, 18, 99-105.	0.6	111
113	Glucose Metabolism in Patients With Schizophrenia Treated With Olanzapine or Quetiapine. <i>Journal of Clinical Psychiatry</i> , 2006, 67, 789-797.	1.1	48
114	A Double-blind Placebo-Controlled Trial of Bupropion Sustained-Release for Smoking Cessation in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 218-225.	0.7	176
115	A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. <i>Psychopharmacology</i> , 2005, 179, 144-150.	1.5	103
116	Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial. <i>Psychopharmacology</i> , 2005, 181, 358-363.	1.5	67
117	A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight Gain. <i>American Journal of Psychiatry</i> , 2005, 162, 954-962.	4.0	136
118	Medical Morbidity and Mortality in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 183-194.	1.1	276
119	Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1116-1121.	1.1	183
120	Independent Effects of Tobacco Abstinence and Bupropion on Cognitive Function in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 1184-1190.	1.1	52
121	Folate, Homocysteine, and Negative Symptoms in Schizophrenia. <i>American Journal of Psychiatry</i> , 2004, 161, 1705-1708.	4.0	127
122	Case 39-2004. <i>New England Journal of Medicine</i> , 2004, 351, 2741-2749.	13.9	15
123	Two-Year Follow-Up of a Smoking Cessation Trial in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 307-311.	1.1	79
124	Attitudes of Schizophrenia Outpatients Toward Psychiatric Medications. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 1372-1376.	1.1	119
125	The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach. <i>Psychotherapy and Psychosomatics</i> , 2003, 72, 115-127.	4.0	407
126	Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 8, 9-14.	1.1	7

#	ARTICLE	IF	CITATIONS
127	Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. <i>Biological Psychiatry</i> , 2002, 51, 493-497.	0.7	104
128	d-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. <i>Schizophrenia Research</i> , 2002, 56, 19-23.	1.1	109
129	Clozapine-Associated Reduction in Arrest Rates of Psychotic Patients With Criminal Histories. <i>American Journal of Psychiatry</i> , 2001, 158, 270-274.	4.0	36
130	A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. <i>Nicotine and Tobacco Research</i> , 2001, 3, 397-403.	1.4	179
131	Adjunctive Antidepressant Drug Therapies in the Treatment of Negative Symptoms of Schizophrenia. <i>CNS Drugs</i> , 1996, 6, 130-147.	2.7	39
132	Implementing Chronic Care Model Treatments for Cigarette Dependence in Community Mental Health Clinics. <i>Journal of Dual Diagnosis</i> , 0, , 1-12.	0.7	1